The reports on NLRC5-mediated regulation of NF-κB and SMAD activation downstream of TNFα and TGFβ, respectively, in the human HSC cell line LX-2 raised the possibility that NLRC5 could be an important regulator of liver fibrosis and NLRC5-deficient mice would be useful to identify and characterize new drug targets to treat liver fibrosis. The gene discussed is TGFB1; the disease is Hepatic fibrosis.